Short answer
BridgeBio Oncology Therapeutics Inc (BBOT) filed its Q3 2026 10-Q quarterly report on Nov 10, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $3M (down 52.9% year over year) with net income of −$34M.
Q3 2026 key financials · XBRL
- Revenue
- $3M
- −52.9% YoY · −8.1% QoQ
- Net income
- −$34M
- +64.3% YoY · +39.5% QoQ
- Operating margin
- -1149.2%
- EPS (diluted)
- $1229.23
- +19040.4% YoY · +274.4% QoQ
Source: XBRL data from the BridgeBio Oncology Therapeutics Inc (BBOT) Q3 2026 10-Q on SEC EDGAR. USD.
BridgeBio Oncology Therapeutics Inc Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- No product revenue in Q3 2026 or Q3 2025, reflecting clinical-stage status
- Operating margin not applicable, operating loss $37.5M vs $49.2M YoY
- R&D strongest focus: $29.6M, down 16% YoY; trial and consumables expenses $20.1M
- Cash, equivalents and marketable securities $315.3M at September 30, 2026, expected to fund at least twelve months
- Operating cash outflow $108.6M vs $71.7M YoY; $500.0M shelf and $200.0M ATM established, with no ATM sales by quarter-end
Risk Factors
- Newly triggered supply-chain risk: BIOSECURE Act enacted December 18, 2025 could restrict Chinese sole-source suppliers
- Most material regulatory update: FDA leadership changes and post-July 2024 Supreme Court ruling increase approval uncertainty
- Clinical risk: Phase 1 trials for BBO-8520, BBO-10203 and BBO-11818 may fail to demonstrate safety or efficacy
- Competitive risk: Two FDA-approved KRASG12C inhibitors compete directly with BBO-8520
- Liquidity risk: Existing cash, cash equivalents and marketable securities expected to fund operations into 2029, not regulatory approval of candidates
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.